Predict your next investment

HEALTHCARE | Biotechnology
stemcentrx.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$520M

Valuation

$0000 

About Stemcentrx

Stemcentrx is developing novel cancer therapies and diagnostics. Stemcentrx is looking to treat cancers by killing cancer stem cells, or cells thought to initiate tumors. These cells are believed to resist standard cancer treatments and enable tumors to spread throughout the body.

Stemcentrx Headquarter Location

450 East Jamie Court 3rd Floor

South San Francisco, California, 94080,

United States

650-491-0120

Latest Stemcentrx News

Boulder-based oncology company Enliven Therapeutics raises $55M Series A

Dec 8, 2020

However, the company has not specified what exact types of cancers it’s seeking to address outside of targeting cancers with “suboptimal drugs,” or published its pipeline of drug candidates. A representative declined to specify more details when reached by BizWest, and Enliven has yet to report its fundraising to the U.S. Securities and Exchange Commission as of Tuesday morning. CEO Sam Kintz and Chief Operating Officer Anish Patel both previously worked at Stemcentrx, a San Francisco-based lung-cancer-drug developer that was acquired by AbbVie Inc. (NYSE: ABBV) in 2016 for $5.8 billion in cash and stock. Stemcentrx’s lung-cancer drug failed to pass Phase III trials last August, and AbbVie later took a $4 billion impairment charge on the acquisition. BOULDER — Enliven Therapeutics Inc., a Boulder-based cancer-drug developer, is exiting from stealth operations by announcing that it raised $55 million in its first funding round. The Series A round includes an unspecified investment from the venture-capital arm of Swiss health-care company Roche Holding AG, the company said in a statement. Life science-focused venture-capital firms Orbimed Advisors LLC and 5AM Venture Management LLC also contributed to the round. Sponsored Content

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Stemcentrx

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Stemcentrx in 2 CB Insights research briefs, most recently on Jun 9, 2021.

Expert Collections containing Stemcentrx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Stemcentrx is included in 5 Expert Collections, including Smart Money VCs (2017-2019).

S

Smart Money VCs (2017-2019)

6,297 items

We crunched the data to identify the 24 VC firms with the best combination of portfolio valuations and investment outcomes.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Stemcentrx Patents

Stemcentrx has filed 30 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Stem cells
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/5/2014

8/21/2018

Monoclonal antibodies, Experimental cancer drugs, Immunology, Clusters of differentiation, Monoclonal antibodies for tumors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/5/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/21/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Immunology, Clusters of differentiation, Monoclonal antibodies for tumors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.